Astrazeneca (AZN) Current Taxes (2016 - 2026)

Astrazeneca has reported Current Taxes over the past 17 years, most recently at -$1.3 billion for Q1 2026.

For Q1 2026, Current Taxes rose 21.56% year-over-year to -$1.3 billion; the TTM value through Mar 2026 reached -$1.3 billion, up 21.56%, while the annual FY2025 figure was -$1.1 billion, 177.1% down from the prior year.
Current Taxes for Q1 2026 was -$1.3 billion at Astrazeneca, down from -$1.1 billion in the prior quarter.
Over five years, Current Taxes peaked at $1.6 billion in Q4 2023 and troughed at -$1.7 billion in Q1 2025.
A 5-year average of -$837.5 million and a median of -$1.2 billion in 2023 define the central range for Current Taxes.
Biggest five-year swings in Current Taxes: soared 76.79% in 2023 and later plummeted 177.1% in 2025.
Year by year, Current Taxes stood at $896.0 million in 2022, then skyrocketed by 76.79% to $1.6 billion in 2023, then dropped by 11.24% to $1.4 billion in 2024, then plummeted by 177.1% to -$1.1 billion in 2025, then dropped by 19.83% to -$1.3 billion in 2026.
Business Quant data shows Current Taxes for AZN at -$1.3 billion in Q1 2026, -$1.1 billion in Q4 2025, and -$1.3 billion in Q3 2025.

Peer Comparison